San Francisco–based anti‑aging biotech NewLimit has raised $435 million in a Series C round led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Eli Lilly Ventures, and other return backers including Kleiner Perkins and Nat Friedman with Daniel Gross. The raise values the company at more than $3 billion, more than tripling its valuation from last year.
The funds will be used to move NewLimit’s first epigenetic “age‑reprogramming” medicine—a liver‑targeted mRNA therapy—into first‑in‑human clinical trials next year, with an initial trial planned for 2027. The company has shown preclinical results where reprogrammed liver cells from a 70‑year‑old donor behaved like those from a 20‑year‑old. NewLimit also plans to expand programs into immune, metabolic, and vascular cells, and may eventually open a clinic or partner with existing healthcare providers to deliver longevity therapies directly to patients.
Sources:
NewLimit raises $435M led by Founders Fund to bring longevity ...
NewLimit Raises $130M to Reverse Aging - Fitt Insider
NewLimit develops age-reversing drug, human clinical trial set for ...
NewLimit Raises $435M Series C for Aging Therapy - AllSci
With $130 Million in Financing, NewLimit Uses Machine ...
Brian Armstrong's NewLimit Raises $435M for Human Trials
Sell or Invest in NewLimit Stock Pre-IPO - Nasdaq Private Market
Brian Armstrong's NewLimit Raises $435M for Human Trials
NewLimit raises $130M to push liver mRNA med into clinic
NewLimit's Funding, Rounds, and Investors - Exa
With $130 Million in Financing, NewLimit Uses Machine Learning to ...
Longevity startup NewLimit raises $435 million for new clinical trials
Beyond the Lab: NewLimit's $130M Series B Fuels the Race to ...